Novozymes AS
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more
Novozymes AS (NVZMY) - Total Assets
Latest total assets as of September 2025: $16.36 Billion USD
Based on the latest financial reports, Novozymes AS (NVZMY) holds total assets worth $16.36 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Novozymes AS - Total Assets Trend (2002–2024)
This chart illustrates how Novozymes AS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Novozymes AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Novozymes AS's total assets of $16.36 Billion consist of 12.4% current assets and 87.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.8% |
| Accounts Receivable | $804.60 Million | 5.3% |
| Inventory | $720.60 Million | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.42 Billion | 29.1% |
| Goodwill | $5.61 Billion | 36.9% |
Asset Composition Trend (2002–2024)
This chart illustrates how Novozymes AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novozymes AS's current assets represent 12.4% of total assets in 2024, a decrease from 45.2% in 2002.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2024, down from 10.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 6.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 36.9% of total assets.
Novozymes AS Competitors by Total Assets
Key competitors of Novozymes AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Akzo Nobel N.V
OTCQX:AKZOF
|
USA | $13.95 Billion |
|
YeSUN Tech Co.Ltd.
KQ:250930
|
Korea | ₩51.65 Billion |
|
Hangzhou Flariant Co Ltd
SHG:605566
|
China | CN¥2.55 Billion |
|
Samhwa Paint
KO:000390
|
Korea | ₩617.09 Billion |
|
DL Holdings CO. LTD.
KO:000210
|
Korea | ₩12.05 Trillion |
|
Norooholdings
KO:000320
|
Korea | ₩1.26 Trillion |
|
Noroo Holdings Co Ltd
KO:000325
|
Korea | ₩1.26 Trillion |
|
Chongqing Sanxia Paints Co Ltd
SHE:000565
|
China | CN¥1.65 Billion |
Novozymes AS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Novozymes AS generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Novozymes AS generates $ 2.01 in net profit.
Novozymes AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.73 | 1.66 |
| Quick Ratio | 1.00 | 1.06 | 1.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $746.00 Million | $ 5.90 Billion | $ 2.75 Billion |
Novozymes AS - Advanced Valuation Insights
This section examines the relationship between Novozymes AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 1.32 |
| Asset Growth Rate (YoY) | -46.5% |
| Total Assets | $15.20 Billion |
| Market Capitalization | $20.10 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novozymes AS's assets above their book value (1.32 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Novozymes AS's assets decreased by 46.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novozymes AS (2002–2024)
The table below shows the annual total assets of Novozymes AS from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $15.20 Billion | -46.48% |
| 2023-12-31 | $28.39 Billion | +1.46% |
| 2022-12-31 | $27.98 Billion | +12.99% |
| 2021-12-31 | $24.77 Billion | +20.76% |
| 2020-12-31 | $20.51 Billion | +0.36% |
| 2019-12-31 | $20.44 Billion | +3.76% |
| 2018-12-31 | $19.70 Billion | +7.21% |
| 2017-12-31 | $18.37 Billion | -1.53% |
| 2016-12-31 | $18.66 Billion | +4.88% |
| 2015-12-31 | $17.79 Billion | -3.45% |
| 2014-12-31 | $18.43 Billion | +11.63% |
| 2013-12-31 | $16.51 Billion | +9.22% |
| 2012-12-31 | $15.11 Billion | +9.18% |
| 2011-12-31 | $13.84 Billion | +9.92% |
| 2010-12-31 | $12.59 Billion | +15.64% |
| 2009-12-31 | $10.89 Billion | +9.72% |
| 2008-12-31 | $9.93 Billion | +11.88% |
| 2007-12-31 | $8.87 Billion | +11.37% |
| 2006-12-31 | $7.96 Billion | +8.98% |
| 2005-12-31 | $7.31 Billion | +2.45% |
| 2004-12-31 | $7.13 Billion | -6.54% |
| 2003-12-31 | $7.63 Billion | -8.59% |
| 2002-12-31 | $8.35 Billion | -- |